Esperion Therapeutics (ESPR) Interest Expenses (2012 - 2026)

Esperion Therapeutics has reported Interest Expenses for 14 years, with the latest figure at $19.8 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 1.89% year-over-year to $19.8 million; the trailing twelve-month figure through Mar 2026 stood at $85.0 million (up 16.57% YoY), and the FY2025 full-year result was $84.6 million, up 42.79% from the prior year.
• Interest Expenses for Q1 2026 stood at $19.8 million, down from $22.6 million in the prior quarter.
• The five-year high for Interest Expenses was $24.7 million in Q4 2024, with the low at $13.7 million in Q2 2024.
• Historically, Interest Expenses has averaged $16.9 million across 5 years, with a median of $15.0 million in 2023.
• Annual changes were most pronounced in 2022 — Interest Expenses surged 73.07% — and 2025, when it retreated 8.2%.
• Esperion Therapeutics' Interest Expenses stood at $14.3 million in 2022, then increased by 5.08% to $15.1 million in 2023, then surged by 63.76% to $24.7 million in 2024, then fell by 8.2% to $22.6 million in 2025, then decreased by 12.54% to $19.8 million in 2026.
• The last three Interest Expenses figures came in at $19.8 million (Q1 2026), $22.6 million (Q4 2025), and $22.1 million (Q3 2025), per Business Quant data.